GIMEMA AML1310 trial of risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia

Venditti, Adriano; Piciocchi, Alfonso; Candoni, Anna; Melillo, Lorella; Calafiore, Valeria; Cairoli, Roberto; de Fabritiis, Paolo; Storti, Gabriella; Salutari, Prassede; Lanza, Francesco; Martinelli, Giovanni; Luppi, Mario; Mazza, Patrizio; Paola Martelli, Maria; Cuneo, Antonio; Albano, Francesco; Fabbiano, Francesco; Tafuri, Agostino; Chierichini, Anna; Tieghi, Alessia; Fracchiolla, Nicola; Capelli, Debora; Foà, Robin; Alati, Caterina; La Sala, Edoardo; Fazi, Paola; Vignetti, Marco; Maurillo, Luca; Buccisano, Francesco; Ilaria Del Principe, Maria; Antonietta Irno-Consalvo, Maria; Ottone, Tiziana; Lavorgna, Serena; Teresa Voso, Maria; Lo‐Coco, Francesco; Arcese, William; Amadori, Sergio

doi:10.1182/blood.2018886960

Public

GIMEMA AML1310 trial of risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia

Published in Blood • Aug 8, 2019

Authors:

Adriano Venditti

Alfonso Piciocchi

Anna Candoni

Abstract

We designed a trial in which postremission therapy of young patients with de novo acute myeloid leukemia (AML) was decided combining cytogenetics/genetics and postconsolidation levels of minimal residual disease (MRD). After induction and consolidation, favorable-risk patients (FR) were to receive a...

Subject

Medicine

Myeloid leukemia

Oncology

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!